Brief: GenSight Biologics Announces Publication of Results from LUMEVOQ Phase I/IIa Clinical Trial REVEAL

Gensight Biologics SA

15/02/2021 06:38

Feb 15 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * ANNOUNCES PUBLICATION OF RESULTS FROM LUMEVOQ® PHASE I/IIA
CLINICAL TRIAL REVEAL IN BIODRUGS
    * EARLY DEMONSTRATION OF FAVORABLE LUMEVOQ® SAFETY PROFILE
IN
HUMAN SUBJECTS SUBSEQUENTLY CONFIRMED IN LATER TRIALS
    * DOSE FOR PHASE III TRIALS SELECTED BASED ON BEST
BENEFIT-RISK
RATIO DEMONSTRATED ACROSS FOUR COHORTS
    * FAVORABLE SAFETY AND TOLERABILITY CONFIRMED OVER 5-YEAR
FOLLOW-UP PERIOD
    * EXPECTS TO REPORT TOPLINE RESULTS FROM ITS THIRD PHASE III
TRIAL
REFLECT IN Q2 2021
    * TRIAL WILL EVALUATE EFFICACY AND SAFETY OF BILATERAL
INJECTIONS
OF LUMEVOQ® IN SUBJECTS WITH LHON CAUSED BY A MUTATED ND4 GENE

Source text for Eikon:  ID:nBw7vzHjDa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))